2017

 

 

130

Grimm MOW, Michaelson DM, Hartmann T (2017) Omega-3 fatty acids, lipids and apoE lipidation in AlzheimerÕs disease: a rationale for multi-nutrient dementia prevention. J Lipid Res. 2017 (IF 4,4 )

 

 

129

Grimm MOW, Mett J, Grimm HS and Hartmann T (2017) APP Function and Lipids: A Bidirectional Link. Front. Mol. Neurosci. 10:63. doi: 10.3389/fnmol.2017.00063 (IF 5.2)

 

 

128

Brandscheid C, Schuck F, Reinhardt S, SchŠfer KH, Pietrzik CU, Grimm M, Hartmann T, Schwiertz A, Endres K Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model J Alzheimers Dis. vol. 56, no. 2, pp. 775-788, 2017 (IF 3,9)

 

2016

 

 

 

 

 

 

127

Grimm MO, Regner L , Mett J , Stahlmann CP, Schorr P , Nelke C, Streidenberger O , Stoetzel H, Winkler J, Zaidan SR, Thiel A, Endres K, Grimm HS, Volmer DA  and Hartmann T. Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for AlzheimerÕs Disease Int J Mol Sci. 2016, 17, 1809; doi:10.3390/ijms17111809 (IF 3)

 

 

126

Grimm MO, Mett J, Hartmann T. The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer«s Disease. Int J Mol Sci. 2016 Oct 26;17(11). pii: E1785 (IF 3)

 

 

125

Wittmann A#, Grimm MO#, Scherthan H, Horsch M, Beckers J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Ford SJ, Burton NC, Razansky D, TrŸmbach D, Aichler M, Walch AK, Calzada-Wack J, Neff F, Wurst W, Hartmann T „, Floss T „. Sphingomyelin Synthase 1 Is Essential for Male Fertility in Mice. PLoS One. 2016 Oct 27;11(10):e0164298. doi: 10.1371/journal.pone.0164298. (IF 3)

# These authors contributed equally to this work. „ These authors are joint last authors on this work.

 

 

124

Reinhardt S, Grimm MO, Stahlmann C, Hartmann T, Shudo K, Tomita T, Endres K Rescue of Hypovitaminosis A induces non-amyloidogenic Amyloid Precursor Protein (APP) Processing. Curr Alzheimer Res. 2016 Jun 2. [Epub ahead of print] (IF 1,76)

 

 

123

Endres K, Reinhardt S, Geladaris A, Knies J, Grimm M, Hartmann T, Schmitt U Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neurosci. 2016 Jul 4;17(1):44. doi: 10.1186/s12868-016-0280-9. (IF 2,3)

 

 

122

Hartmann T Verhindern und Verzšgern: Implementationsparameter der sekundŠren PrŠvention bei der Alzheimer Krankheit. Angewandte Forschung 2016; (4) 28-31

 

 

121

Grimm MOW, Mett J, Stahlmann CP, Haupenthal V, BlŸmel T, Stštzel H, Grimm HS, Hartmann T Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) increase Aβ-degradation by affecting insulindegrading enzyme (IDE). Biochem Cell Biol, 2016 Dec;94(6):534-542

 

 

120

Illario M, Maione A, Rusciano M, Goossens E, Rauter A, Braz N, Jager-Wittenaar H, Somma C, Crola C, Soprano M, Vuolo L, Campiglia P, Iaccarino G, Griffiths H, Hartmann T, Tramontano D, Annama Nutrilive: An integrated nutritional approach as a sustainable tool to prevent malnutrition in   older people and promote active and healthy ageing. The EIP-AHA Nutrition Action Group. Adv in Pub Health, Volume 2016, Article ID 5678782, 9 pages http://dx.doi.org/10.1155/2016/5678782

 

 

119

Grimm MO, Haupenthal VJ, Mett J, Stahlmann CP, BlŸmel T, Mylonas NT, Endres K, Grimm HS, Hartmann T. Oxidized Docosahexaenoic Acid Species and Lipid Peroxidation Products Increase Amyloidogenic Amyloid Precursor Protein Processing. Neurodegener Dis 2016;16:44–54 (IF 3,4)

 

2015

 

 

118

Mett J, Hartmann T, Grimm MOW. The effects of glycerophospholipids and fatty acids on APP processing: Implications for alzheimer's disease. Handbook of Lipids in Human Function: Fatty Acids, December 04, 2015, Pages 377-421

 

 

117

Blacher E, Dadali T, Bespalko A, Haupenthal VJ, Grimm MO, Hartmann T, Lund FE, Stein R, Levy A. AlzheimerÕs disease pathology is attenuated in a CD38 deficient mouse model. Annals in Neurology. 2015 Apr 20. doi: 10.1002/ana.24425 (IF 11,9)

 

 

116

Grimm MO, Stahlmann CP, Mett J, Haupenthal VJ, Zimmer VC, Lehmann J, Hundsdšrfer B, Endres K, Grimm HS, Hartmann T. Vitamin E: Curse or Benefit in Alzheimer«s Disease? A Systematic Investigation of the Impact of α-, γ- and δ-Tocopherol on A§ Generation and Degradation in Neuroblastoma Cells. J Nutr Health Aging. 2015;19(6):646-56 (IF 3)

 

 

115

Marcus Otto Grimm, Janine Mett, Christoph Peter Stahlmann, Sven Gršsgen, Viola Jessica Haupenthal, Tamara BlŸmel, Benjamin Hundsdšrfer, Valerie Christin Zimmer, Nadine Tamara Mylonas, Heikki Tanila, Ulrike MŸller, Heike Sabine Grimm, Tobias Hartmann. APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression. Front. Aging Neurosci. 2015 doi: 10.3389/fnagi.2015.00077 (IF 4,7)

 

2014

 

 

114

Stahl R, Schilling S, Soba P, Rupp C, Hartmann T, Wagner K, Merdes G, Eggert S, Kins S. Shedding of APP limits its synaptogenic activity and cell adhesion properties. Frontiers in Cellular Neuroscience 11/2014; 8(410). į (IF 4.47)

 

 

113

Grimm MO, Hundsdšrfer B, Gršsgen S, Mett J, Zimmer VC, Stahlmann CP, Haupenthal VJ, Rothhaar TL, Lehmann J, PŠtzold A, Zinser EG, Tanila H, Shen J, MŸller U, Grimm HS, Hartmann T. PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer's disease. Cell Physiol Biochem. 2014;34(1):92-110. doi: 10.1159/000362987. Epub 2014 Jun 16. (IF 3.55)

 

 

112

Hartmann T, van Wijk N, Wurtman RJ, Olde Rikkert MGM, Sijben JWC, Soininen H, Vellas B, Scheltens P. A nutritional approach to ameliorate altered phospholipid metabolism in AD. J AlzheimerÕs Disease. 2014 Jan 1;41(3):715-7. doi: 10.3233/JAD-141137 (IF 4.2)

 

 

111

Karaca I, Tamboli IY, Glebov K, Richter J, Fell LH, Grimm MO, Haupenthal VJ, Hartmann T, GrŠler MH, van Echten-Deckert G, Walter J. Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. J Biol Chem. 2014 May 7 (IF4.7)

 

 

110

Koivisto, Grimm, Rothhaar, Berkecz, LŸtjohann, Giniatullina, Takalo, Miettinen, Lahtinen, Giniatullin, Penke, Jan‡ky, Broersen, Hartmann, Tanila. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. J Nutri Biochem 2014 Feb;25(2):157-69. doi: 10.1016/j.jnutbio.2013.09.015. Epub 2013 Nov 6 (IF4.7)

 

 

109

Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T. The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer's Disease. Biomed Res Int. 2013;2013:814390. Epub 2014 (IF2.4)

 

 

108

Robinson, Gršsgen, Mett, Zimmer, Haupenthal, Hundsdšrfer, Stahlmann, Slobodskoy, MŸller, Hartmann, Stein, Grimm. Upregulation of PGC-1α expression by AlzheimerÕs disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP. Aging Cell. 2014 Apr;13(2):263-72. doi: 10.1111/acel.12183. Epub 2013 Dec 17. (IF7.55)

 

 

107

Grimm MO, Lehmann J, Mett J, Zimmer VC, Grosgen S, Stahlmann CP, Hundsdorfer B, Haupenthal VJ, Rothhaar TL, Herr C, Bals R, Grimm HS, Hartmann T. Impact of Vitamin D on Amyloid Precursor Protein Processing and Amyloid-beta Peptide Degradation in Alzheimer's Disease. Neurodegener Dis 2014 2014;13(2-3):75-81. doi: 10.1159/000355462. Epub 2013 Oct 30 (IF3.6)

 

 

106

Reinhardt S, Schuck F, Grosgen S, Riemenschneider M, Hartmann T, Postina R, Grimm M, Endres K. Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in AlzheimerÕs disease. FASEB J. 2014 Feb;28(2):978-97. doi: 10.1096/fj.13-234864. Epub 2013 Oct 28  (IF5.7)

 

 

105

Hausner L, TschŠpe JA, Schmitt HP, Hentschel F, Hartmann T, Fršlich L. Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. Alzheimers Dement. 2014 Mar;10(2):e27-39. doi: 10.1016/j.jalz.2013.02.006. Epub 2013 Jul 11 (IF14.5)

 

2013

 

 

104

Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci. 2013 Dec 23;5:98. (IF5.2)

 

 

103

Xie K, Liu Y, Hao W, Walter S, Penke B, Hartmann T, Schachner M, Fassbender K. Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice. Neurobiol Aging. 2013 Oct;34(10):2389-98 (IF6.2)

 

 

102

Grimm MOW, Hartmann T. Recent Understanding of the Molecular Mechanisms of AlzheimerÕs Disease. J Add Res & Ther 2012 Special Issue: Psychiatric Disorders:1-15. (IF1.33)

 

 

101

Grimm MO, Haupenthal VJ, Rothhaar TL, Zimmer VC, Gršsgen S, Hundsdšrfer B, Lehmann J, Grimm HS, Hartmann T. Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer's Disease. Int J Mol Sci. 2013 Mar 13;14(3):5879-98 (IF2.5)

 

 

100

Burg, Grimm, Rothhaar, Gršsgen, Hundsdšrfer, Haupenthal, Zimmer, Mett, WeingŠrtner, Laufs, Broersen, Tanila, Vanmierlo, LŸtjohann,  Hartmann,, Marcus O.W. Grimm. Plant sterols the better cholesterol in Alzheimer«s disease? A mechanistical study, J Neuroscience, 2013; 33:16072-16087 (IF7.3)

 

2012

 

 

99.

Grimm MO, Zinser EG, Gršsgen S, Hundsdšrfer B, Rothhaar TL, Burg VK, Kaestner L, Bayer TA, Lipp P, MŸller U, Grimm HS, Hartmann T. Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking AlzheimerÕs disease pathology with ganglioside metabolism. PLoS One, 2012; 7(3):e34095

 

 

98.

Rothhaar TL, Gršsgen S, Haupenthal VJ, Burg VK, Hundsdšrfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO. Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease. ScientificWorldJournal. 2012;2012:141240.

 

 

97.

Gries M, Davies L, Liu Y, Bachhuber A, Spiegel J, Dillmann U, Hartmann T, Fassbender K, Walter S. Response of Toll-like receptors in experimental Guillain-BarrŽ syndrome: A kinetic analysis. Neurosci Lett. 2012 Jun 19;518(2):154-60

 

 

96.

Vanmierlo T, Weingartner O, van der Pol S, Husche C, Kerksiek A, Friedrichs S, Sijbrands E, Steinbusch H, Grimm M, Hartmann T, Laufs U, Bohm M, de Vries HE, Mulder M, Lutjohann D (2012) Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. J Lipid Res. 2012 Apr;53(4):726-35

 

 

95.

Grimm MO, Rothhaar TL, Hartmann T. The role of APP proteolytic processing in lipid metabolism. Exp Brain Res. 2012 Apr;217(3-4):365-75

 

 

94.

Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K. TLR2 Is a Primary Receptor for AlzheimerÕs Amyloid beta Peptide To Trigger Neuroinflammatory Activation. J Immunol. 2012 Feb 1;188(3):1098-107

 

 

93.

Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lutjohann D, Broersen LM, Hartmann T, Michaelson DM (2012) The Isoform-Specific Pathological Effects of ApoE4 in vivo are Prevented by a Fish Oil (DHA) Diet and are Modified by Cholesterol. J Alzheimers Dis. 2012;28(3):667-83.

 

 

92.

Grimm MO, Rothhaar TL, Grosgen S, Burg VK, Hundsdorfer B, Haupenthal VJ, Friess P, Kins S, Grimm HS, Hartmann T (2011) Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J Nutr Biochem. 2012 Oct;23(10):1214-23. doi: 10.1016/j.jnutbio.2011.06.015. Epub 2011 Dec 29

 

2011

 

91.

Hartmann T, Prinetti A (2011) Going the wrong road: Fyn and targeting of amyloid precursor protein to lipid rafts. J Neurochem 118:677-679.

 

 

90.

SchŠfer KH, Braun A, Semar S, Letiembre M, Klotz M, Klein JC, Grimm MO, Micci MA, Tagliatela G, Liu Y, Fassbender, K, Hartmann T,.  Alzheimers Disease Affects the Enteric Nervous System. Gastroenterology. 2011 May 140 (5) S54-50

 

 

89.

Grimm MO, Kuchenbecker J, Grosgen S, Burg VK, Hundsdorfer B, Rothhaar TL, Friess P, de Wilde MC, Broersen LM, Penke B, Peter M, Vigh L, Grimm HS, Hartmann T (2011) Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 286:14028-14039.

 

 

88.

Grimm, M.O.W., S. Groesgen, T. L. Rothhaar, V. K. Burg, B. Hundsdoerfer, V. J. Haupenthal, P. Friess, U. Mueller, K. Fassbender, M. Riemenschneider, H. S. Grimm,  T. Hartmann (2011). Intracellular APP domain (AICD) regulates serine-palmitoyl-CoA transferase (SPT) expression and is affected in Alzheimer's disease.  I J Alzheimer's disease 2011, Article ID 695413,1-8

 

 

87.

Grimm MO, Grosgen S, Riemenschneider M, Tanila H, Grimm HS, Hartmann T (2011) From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A 1218:7713-7722

 

 

86.

Vanmierlo, T., J. Popp, H. Kšlsch, S. Friedrichs, F. Jessen, B. Stoffel-Wagner, T. Bertsch, T. Hartmann, W. Maier, K. von Bergmann, H. Steinbusch, M. Mulder, D. LŸtjohann (2011) The plant sterol brassicasterol as additional CSF biomarker in AlzheimerÕs disease. Acta Psychiatr. Scand: 1-9

 

 

85.

Hao, W., Y. Liu, S. Liu, S. Walter, M.O. Grimm, A. J.  Kiliaan, B. Penke, T. Hartmann, C.E. RŸbe, M.D. Menger, K. Fassbender (2011). Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain 134, 278-92 (IF 10.2)

 

 

84.

Grimm, M.O.W, J. Kuchenbecker, T. L. Rothhaar, S. Gršsgen, B. Hundsdšrfer, V.K. Burg, P. Friess, U. MŸller, H.S.  Grimm, M. Riemenschneider, T. Hartmann, (2011). Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase (AGPS) by amyloid precursor protein (APP) processing and is affected in Alzheimer's disease. J Neurochem 116, 916-25.

 

 

83.

Clarke,  N. A.,  T. Hartmann,  E. L. Jones, C. G Ballard,  P. T. Francis, (2011). Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid A§ 40 and tau in patients with intractable unipolar depression. INT J GERIATR PSYCH 26 1283-91

 

2010

82.

Gršsgen, S., M.O. Grimm, P. Friess, T. Hartmann T, (2010) Role of amyloid beta in lipid homeostasis.  Biochim Biophys Acta 1801: 966-974.

2009

81.

Verwey, N.A., W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, P.P. De Deyn, D. Galasko, H. Hampel, T. Hartmann, E. Kapaki, L. Lannfelt, P.D. Mehta, L. Parnetti, A. Petzold, T. Pirttila, L. Saleh, A. Skinningsrud, J.C. Swieten, M.M. Verbeek, J. Wiltfang, S. Younkin, P. Scheltens, and M.A. Blankenstein, (2009). A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in AlzheimerÕs disease. Ann Clin Biochem. 46: p. 235-40

80.

Uhrig, M., C. Ittrich, V. Wiedmann, Y. Knyazev, A.  Weninger, M. Riemenschneider, and T.  Hartmann (2009). Novel Relationship between neurogenin 2 and KIAA0125 Revealed by Clustering of Alzheimer Amyloid beta Responsive Genes in Human Neuroblastoma Cells. PLoS One. 2009 Aug 26;4(8):e6779

2008

79.

Uhrig, M., P. Brechlin, O. Jahn, Y. Knyazev, A. Weninger, L. Busia, M. Otto, and T. Hartmann, (2008). Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces the differentiation potential. BMC Medicine 6:38

78.

Tschaepe, J.A., M.O.W. Grimm, H.S. Grimm, and T. Hartmann, (2008). Cholesterol and A beta production: Methods for analysis of altered cholesterol De Novo synthesis. ADVANCES IN ALZHEIMERÕS AND PARKINSONÕS DISEASE. INSIGHTS, PROGRESS, AND PERSPECIVES (57): 221-230

77.

Nadler, Y., A. Alexandrovich, N. Grigoriadis, T. Hartmann, KS. Rao, E. Shohami, and R. Stein, (2008). Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia 56(5):552-67

76.

Grimm, M.O., H.S. Grimm, I. Tomic, K. Beyreuther, C. Bergmann*, and T. Hartmann*, (2008). Independent Inhibition of Alzheimer Disease {beta}- and {gamma}-Secretase Cleavage by Lowered Cholesterol Levels. J Biol Chem, 283: p. 11302-11.

This work has been awarded with the Steinberg-Krupp price for Alzheimer Research 2009

2007

75.

Zinser, E.G., T. Hartmann, and M.O. Grimm, (2007). Amyloid beta-protein and lipid metabolism. Biochim Biophys Acta, 1768: p. 1991-2001.

74.

Letiembre, M., W. Hao, Y. Liu, S. Walter, I. Mihaljevic, S. Rivest, T. Hartmann, and K. Fassbender, (2007). Innate immune receptor expression in normal brain aging. Neuroscience, 146(1): p. 248-254

73.

Hartmann, T., J. Kuchenbecker, and M.O. Grimm, (2007). Alzheimer's disease: the lipid connection. J Neurochem, 103 Suppl 1: p. 159-70.

72.

Hartmann, T., K. Fassbender, and M.O.W. Grimm, (2007). Alzheimer's disease prevention - The emerging role of lipids and diet. OCL - Oleagineux Corps Gras Lipides 14 (3-4), p. 182-185

71.

Grimm, M.O.W., J. Kuchenbecker, E. Zinser, and T. Hartmann, (2007). Plasmalogens and APP-processing: Method for the analysis of altered plasmalogen. New Trends in Alzheimer and Parkinson Related Disorders: ADPD2007: 161-166

70.

Grimm, M.O., H.S. Grimm, and T. Hartmann, (2007). Amyloid beta as a regulator of lipid homeostasis. Trends Mol Med, 13: p. 337-44.

2006

69.

TschŠpe, J., and T. Hartmann, (2006). Therapeutic Perspectives in Alzheimer's Disease. Rec. Pat. CNS Drug Discov., 1: p. 119-127.

68.

Schneider, A., W. Schulz-Schaeffer, T. Hartmann, J.B. Schulz, and M. Simons, (2006). Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis, 23: p. 573-7.

67.

Oksman, M., H. Iivonen, E. Hogyes, Z. Amtul, B. Penke, I. Leenders, L. Broersen, D. Lutjohann, T. Hartmann, and H. Tanila, (2006). Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis, 23: p. 563-72.

66.

Liu, Z., Y. Ruan, W. Yue, Z. Zhu, T. Hartmann, K. Beyreuther, and D. Zhang, (2006). GM1 up-regulates Ubiquilin 1 expression in human neuroblastoma cells and rat cortical neurons. Neurosci Lett, 407: p. 59-63.

65.

Hartmann, T., (2006). Role of Amyloid Precursor Protein, Amyloid-beta and gamma-Secretase in Cholesterol Maintenance. Neurodegener Dis, 3: p. 305-11.

64.

Grimm, M.O., J.A. Tschape, H.S. Grimm, E.G. Zinser, and T. Hartmann, (2006). Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurol Scand Suppl, 185: p. 27-32.

63.

Yavich, L., M. Oksman, H. Tanila, P. Kerokoski, M. Hiltunen, T. van Groen, J. Puolivali, P.T. Mannisto, A. Garcia-Horsman, E. MacDonald, K. Beyreuther, T. Hartmann, and P. Jakala, (2005). Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis, 20: p. 303-13.

62.

Grimm MOW, Zinser E, Grimm H, Wilk S, Mueller U, Hartmann T (2006) Link between APP-processing, Alzheimer disease and glycosphingolipid metabolism. Journal of Neurochemistry (99): 12-12

2005

61.

Blankenstein MA, Clark C, De Deyn PP, Galasko D, Hartmann T, Hampel H, Kapaki E, Mehta PD, Parnetti L, Pirttila T, Verbeek MM, Wiltfang J, Blennow K (2005) Multicenter comparison of assays for cerebrospinal fluid (CSF) markers for Alzheimer disease. CLINICA CHIMICA ACTA   (355):S175-S175

60.

Fisher A, Brandeis R, Pittel Z, Haring R, Sparks L, Hartmann T, Inestrosa N, Farias G, Bons N, Bar-Ner N, Natan N, Beach TG (2005) M1 muscarinic agonists - Modulation of hallmarks in Alzheimer's disease (AD) and in cerebral amyloid angiopathy (CAA). J Neurological Sci (229): 338-338

59.

Li, W., N. West, E. Colla, O. Pletnikova, J.C. Troncoso, L. Marsh, T.M. Dawson, P. Jakala, T. Hartmann, D.L. Price, and M.K. Lee, (2005). Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A, 102: p. 2162-7.

58.

Levi, O., D. Lutjohann, A. Devir, K. von Bergmann, T. Hartmann, and D.M. Michaelson, (2005). Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J Neurochem, 95: p. 987-97.

57.

Hartmann, T., LIPIDIET, in Nutrition & Ageing, R. D'Amario, Editor. 2005, European Commission: Brussels. p. 19-20.

56.

Hartman, T., (2005). Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. Subcell Biochem, 38: p. 365-80.

55.

Grimm, M.O., H.S. Grimm, A.J. Patzold, E.G. Zinser, R. Halonen, M. Duering, J.A. Tschape, B. De Strooper, U. Muller, J. Shen, and T. Hartmann, (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol, 7: p. 1118-23.

54.

Grimm, M.O., A.J. Paetzold, H.S. Grimm, E.G. Zinser, T. Ruppert, and T. Hartmann, Linking Alzheimer's disease, b-Amyloid, and Lipids: A technical approach., in Amyloid Precursor Protein - A practical approach., W. Xia and H. Xu, Editors. 2005, CRC Press: Boca Raton, FL. p. 129-144.

53.

Duering, M., M.O. Grimm, H.S. Grimm, J. Schroder, and T. Hartmann, (2005). Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging, 26: p. 785-8.

2004

52.

Zha, Q., Y. Ruan, T. Hartmann, K. Beyreuther, and D. Zhang, (2004). GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry, 9: p. 946-52.

51.

Gouras, G., F. LaFerla, G. Strobel, J. Busciglio, C. Almeida, C. Geula, C. Stenh, D. Lee, M. D'Andrea, B. Nagele, R. Takahashi, T. Hartmann, A. LeBlanc, K. Dineley, and A. Koudinov, (2004). Intraneuronal A§ accumulation-more evidence, less controversy? Journal of Alzheimer's Disease, 6: p. 443-449.

50.

Fassbender, K., S. Walter, S. Kuhl, R. Landmann, K. Ishii, T. Bertsch, A.K. Stalder, F. Muehlhauser, Y. Liu, A.J. Ulmer, S. Rivest, A. Lentschat, E. Gulbins, M. Jucker, M. Staufenbiel, K. Brechtel, J. Walter, G. Multhaup, B. Penke, Y. Adachi, T. Hartmann, and K. Beyreuther, (2004). The LPS receptor (CD14) links innate immunity with Alzheimer's disease. Faseb J, 18: p. 203-5.

49.

Echeverria, V., A. Ducatenzeiler, E. Dowd, J. Janne, S.M. Grant, M. Szyf, F. Wandosell, J. Avila, H. Grimm, S.B. Dunnett, T. Hartmann, L. Alhonen, and A.C. Cuello, (2004). Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience, 129: p. 583-92.

2003

48.

Schonknecht, P., J. Pantel, T. Hartmann, E. Werle, M. Volkmann, M. Essig, M. Amann, N. Zanabili, H. Bardenheuer, A. Hunt, and J. Schroder, (2003). Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res, 120: p. 231-8.

47.

Hartmann, T. and K. Beyreuther, Therapeutische Perspektiven der Alzheimer-Demenz, in Lehrbuch der Gerontopsychatrie und -psychotherapie, H. Fšrstel, Editor. 2003, Thieme: Stuttgart, New York. p. 273-279.

46.

Grziwa, B., M.O. Grimm, C.L. Masters, K. Beyreuther, T. Hartmann and S.F. Lichtenthaler, (2003). The Transmembrane Domain of the Amyloid Precursor Protein in Microsomal Membranes Is on Both Sides Shorter than Predicted. J Biol Chem, 278: p. 6803-6808.

45.

Grimm, H.S., D. Beher, S.F. Lichtenthaler, M.S. Shearman, K. Beyreuther, and T. Hartmann, (2003). gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J Biol Chem, 278: p. 13077-85.

44.

Gamliel, A., C. Teicher, T. Hartmann, K. Beyreuther, and R. Stein, (2003). Overexpression of wild-type presenilin 2 or its familial Alzheimer's disease-associated mutant does not induce or increase susceptibility to apoptosis in different cell lines. Neuroscience, 117: p. 19-28.

2002

43.

Wood, G.B., A.R. Koudinov, T.G. Ohm, K. Yanagisawa, J. McLaurin, G.P. Eckert, W.E. MŸller, T. Hartmann, and F. Fahrenholz, (2002). Cholesterol and Alzheimer's disease. Neurobiology of lipids, 1: p. 1-12.

42.

Simons, M., F. Schwarzler, D. LŸtjohann, K. von Bergmann, K. Beyreuther, J. Dichgans, H. Wormstall, T. Hartmann, and J.B. Schulz, (2002). Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol, 52: p. 346-50.

41.

Schšnknecht, P., D. LŸtjohann, J. Pantel, H. Bardenheuer, T. Hartmann, K. von Bergmann, K. Beyreuther, and J. Schršder, (2002). Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett, 324: p. 83-5.

40.

Runz, H., J. Rietdorf, I. Tomic, M. de Bernard, K. Beyreuther, R. Pepperkok, and T. Hartmann, (2002). Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci, 22: p. 1679-89.

39.

Hartmann, T. and K. Beyreuther, Molekulare Pathologie, in Demenzen, K. Beyreuther, et al., Editors. 2002, Thieme Lehrbuch: Stuttgart, New York. p. 99-105.

38.

Grimm, M.O., I. Tomic, and T. Hartmann, (2002). Potential external source of A beta in biological samples. Nat Cell Biol, 4: p. E164-5.

37.

Gamliel, A., C. Teicher, D.M. Michaelson, L. Pradier, T. Hartmann, K. Beyreuther, and R. Stein, (2002). Increased expression of presenilin 2 inhibits protein synthesis. Mol Cell Neurosci, 19: p. 111-24.

36.

Grimm, M.O.W., J. Kuchenbecker, E.G. Zinser, and T. Hartmann, Plasmalogens and APP-Processing: Method for the Analysis of Altered Plasmalogen Homeostasis, in New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007, I. Hanin, et al., Editors. 2008: Salzburg   Austria. p. 312.

2001

35.

Schšnknecht, P., J. Pantel, K. Klinga, M. Jensen, T. Hartmann, B. Salbach, and J. Schršder, (2001). Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease. Neurosci Lett, 307: p. 122-4.

34.

Jauss, M., K. Herholz, L. Kracht, J. Pantel, T. Hartmann, M. Jensen, M. Essig, and J. Schroder, (2001). Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients. Eur Arch Psychiatry Clin Neurosci, 251: p. 225-31.

33.

Hartmann, T. and K. Beyreuther, (2001). Alzheimer (Review). Universitas, 56: p. 451-464.

32.

Hartmann, T. and K. Beyreuther, Der unaufhaltsame Zerfall (Review), in Ruperto Carola Forschungsmagazin. 2001. p. 25-31.

31.

Hartmann, T., (2001). Cholesterol, Abeta and Alzheimer's disease (Review). TINS, 24: p. 45-48.

30.

Grimm, H.S., S. Lichtenthaler, K. Beyreuther, and T. Hartmann, Intracellular and secreted Abeta40/42 ratios are differently influenced by APP mutations, in Alzheimer's disease: Advances in Etiology, Pathogenesis and Therapeutics, K. Iqbal, et al., Editors. 2001, wiley. p. 479-486.

29.

Fassbender, K., M. Simons, C. Bergmann, M. Stroick, D. LŸtjohann, P. Keller, H. Runz, S. KŸhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther, and T. Hartmann, (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A, 98: p. 5856-61.

28.

Blasko, I., A. Apochal, G. Boeck, T. Hartmann, B. Grubeck-Loebenstein, and G. Ransmayr, (2001). Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis, 8: p. 1094-101.

27.

Bayer, T.A., O. Wirths, K. Majtenyi, T. Hartmann, G. Multhaup, K. Beyreuther, and C. Czech, (2001). Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport (Review). Brain Pathol, 11: p. 1-11.

2000

26.

Schšnknecht, P., J. Pantel, E. Werle, T. Hartmann, M. Essig, K. Baudendistel, K. Beyreuther, and J. Schršder, (2000). Cerebrospinal fluid protein levels in the differential diagnosis of Alzheimer's disease. Fortschr Neurol Psychiatr, 68: p. 439-46.

25.

Leloup, C., D.M. Michaelson, A. Fisher, T. Hartmann, K. Beyreuther, and R. Stein, (2000). M1 muscarinic receptors block caspase activation by phosphoinositide 3- kinase- and MAPK/ERK-independent pathways. Cell Death Differ, 7: p. 825-33.

24.

Jensen, M., T. Hartmann, B. Engvall, R. Wang, S.N. Uljon, K. Sennvik, J. Naslund, F. Muehlhauser, C. Nordstedt, K. Beyreuther, and L. Lannfelt, (2000). Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med, 6: p. 291-302.

23.

Ishii, K., F. MŸlhauser, U. Liebl, M. Picard, S. KŸhl, B. Penke, T. Bayer, M. Wiessler, M. Hennerici, K. Beyreuther, T. Hartmann, and K. Fassbender, (2000). Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase. Faseb J, 14: p. 1485-9.

22.

Culvenor, J.G., C.A. McLean, B.C. Campbell, C.L. Masters, Q.X. Li, P. Jakala, T. Hartmann, and K. Beyreuther, (2000). The Role of NAC in Amyloidogenesis in Alzheimer's Disease. Am J Pathol, 156: p. 734-736.

1999

21.

Jensen, M., J. Schršder, M. Blomberg, B. Engvall, J. Pantel, N. Ida, H. Basun, L.O. Wahlund, E. Werle, M. Jauss, K. Beyreuther, L. Lannfelt, and T. Hartmann, (1999). Cerebrospinal fluid A beta42 is increased early in sporadic AlzheimerÕs disease and declines with disease progression. Ann Neurol, 45: p. 504-11.

20.

Hartmann, T., (1999). Intracellular biology of AlzheimerÕs disease amyloid beta peptide (Review). Eur Arch Psychiatry Clin Neurosci, 249: p. 291-8.

19.

Evin, G., G. Reed, J.E. Tanner, Q.X. Li, J.G. Culvenor, S.J. Fuller, H. Wadsworth, D. Allsop, R.V. Ward, E.H. Karran, C.W. Gray, T. Hartmann, S.F. Lichtenthaler, A. Weidemann, K. Beyreuther, and C. Masters, Characterisation of g-secretase candidates from human brain using a new Western blot assay, in AlzheimerÕs disease and related disorders, K. Iqbal, et al., Editors. 1999, John Wiley & sons: New York. P. 411-418.

18.

Culvenor, J.G., C.A. McLean, S. Cutt, B.C. Campbell, F. Maher, P. Jakala, T. Hartmann, K. Beyreuther, C.L. Masters, and Q.X. Li, (1999). Non-Abeta component of AlzheimerÕs disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol, 155: p. 1173-81.

17.

Christie, G., R.E. Markwell, C.W. Gray, L. Smith, F. Godfrey, F. Mansfield, H. Wadsworth, R. King, M. McLaughlin, D.G. Cooper, R.V. Ward, D.R. Howlett, T. Hartmann, S.F. Lichtenthaler, K. Beyreuther, J. Underwood, S.K. Gribble, R. Cappai, C.L. Masters, A. Tamaoka, R.L. Gardner, A.J. Rivett, E.H. Karran, and D. Allsop, (1999). AlzheimerÕs disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J Neurochem, 73: p. 195-204.

16.

Blasko, I., F. Marx, E. Steiner, T. Hartmann, and B. Grubeck-Loebenstein, (1999). TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. Faseb J, 13: p. 63-8.

15.

Bayer, T.A., P. JŠkŠlŠ, T. Hartmann, R. Egensperger, R. Buslei, P. Falkai, and K. Beyreuther, (1999). Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport, 10: p. 2799-803.

14.

Bayer, T.A., P. JŠkŠlŠ, T. Hartmann, L. Havas, C. McLean, J. Culvenor, Q. Li, C.L. Masters, P. Falkai, and K. Beyreuther, (1999). Alpha Synuclein accumulates in Lewy bodies in ParkinsonÕs disease and dementia with Lewy bodies but not in AlzheimerÕs disease beta-amyloid plaque cores. Neuroscience Letters, 266: p. 213-216.

1998

13.

Culvenor, J.G., A. Henry, T. Hartmann, G. Evin, D. Galatis, A. Friedhuber, U.L. Jayasena, J.R. Underwood, K. Beyreuther, C.L. Masters, and R. Cappai, (1998). Subcellular localization of the AlzheimerÕs disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid, 5: p. 79-89.

1997

12.

Schršder, J., J. Pantel, N. Ida, M. Essig, K. Baudendistel, T. Hartmann, M. Knopp, C. Masters, and K. Beyreuther, (1997). Cerebral Atrophy and cerebrospinal fluid §-amyloid in dementia of the AlzheimerÕs type: A study with quantitative magnetic resonance imaging. NeuroImage, 5.

11.

Schršder, J., J. Pantel, N. Ida, M. Essig, T. Hartmann, M. Knopp, L. Schad, R. Sandbrink, H. Sauer, C. Masters, and K. Beyreuther, (1997). Cerebral changes and cerebrospinal fluid beta-amyloid in AlzheimerÕs disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry, 6: p. 505-507.

10.

Hartmann, T., S.C. Bieger, B. BrŸhl, P.J. Tienari, N. Ida, D. Allsop, G.W. Roberts, C.L. Masters, C.G. Dotti, K. Unsicker, and K. Beyreuther, (1997). Distinct sites of intracellular production for AlzheimerÕs disease Ab40/42 amyloid peptides. Nat-Med, 3: p. 1016-20.

9.

Allsop, D., G. Christie, C. Gray, S. Holmes, R. Markwell, D. Owen, L. Smith, H. Wadsworth, R.V. Ward, T. Hartmann, S. Lichtenthaler, G. Evin, S. Fuller, E. Tanner, C. Masters, K. Beyreuther, and G.W. Roberts, Studies on the inhibition of the beta-amyloid formation in APP751-transfected IMR-32 cells, and SPA4CT-transfected SH-SY5Y cells, in AlzheimerÕs disease, K. Iqbal, et al., Editors. 1997, John Wiley & Sons Ltd. P. 717-728.

1996

8.

Tienari, P., B. De Strooper, E. Ikonen, M. Simons, A. Weidemann, C. Czech, T. Hartmann, N. Ida, G. Multhaup, C. Masters, F. Van Leuven, K. Beyreuther, and C. Dotti, (1996). The b-amyloid domain is essential for axonal sorting of amyloid precursor protein. EMBO J., 16: p. 5218-5229.

7.

Sandbrink, R., T. Hartmann, C. Masters, and K. Beyreuther, (1996). Genes Contributing to AlzheimerÕs Disease. Molec Psychiatry, 1: p. 27-40.

6.

Ida, N., T. Hartmann, J. Pantel, J. Schršder, R. Zerfass, H. Fšrstel, R. Sandbrink, C. Masters, and K. Beyreuther, (1996). Analysis of heterogenous §A4 peptides in human cerebrospinal fluid and blood by a newly-developed sensitive Western blot assay. J Biol Chem, 271: p. 22908-22914.

5.

Hartmann, T., C. Bergsdorf, R. Sandbrink, P.J. Tienari, G. Multhaup, N. Ida, S. Bieger, T. Dyrks , A. Weidemann, C.L. Masters, and K. Beyreuther, (1996). AlzheimerÕs Disease §A4 Protein Release and APP Sorting Are Regulated by Alternative Splicing. J. Biol. Chem., 271: p. 13208-13214.

1994

4.

Fšrstl, H., C. Czech, H. Sattel, C. Geiger Kabisch, C. Besthorn, S. Kreger, U. Mšnning, T. Hartmann, C. Masters, and K. Beyreuther, (1994). Apolipoprotein E and Alzheimer dementia. Personal results and brief literature review. Nervenarzt, 65: p. 780-6.

1993

3.

Dyrks, T., E. Dyrks, T. Hartmann, C. Masters, and K. Beyreuther, Radicals as Mediators for the Amyloidogenic Transformation of §A4-bearing APP-Fragments, in AlzheimerÕs disease: Advances in Clinical and Basic Research, B. Corain, et al., Editors. 1993, John Wiley & Sons Ltd. P. 497 – 506.

2.

Czech, C., U. Mšnning, P.J. Tienari, T. Hartmann, C. Masters, K. Beyreuther, and H. Fšrstel, (1993). Apolipoprotein E-e4 allele and AlzheimerÕs disease. Lancet, 342: p. 1309-1310.

1992

1.

Dyrks, T., E. Dyrks, T. Hartmann, C. Masters, and K. Beyreuther, (1992). Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem, 267: p. 18210-7.